ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its price target lowered by analysts at UBS Group AG from $4.00 to $2.20. They now have a "buy" rating on the stock.
MediumReport
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its price target lowered by analysts at UBS Group AG from $4.00 to $2.20. They now have a "buy" rating on the stock.
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its price target lowered by analysts at HC Wainwright from $25.00 to $5.00. They now have a "buy" rating on the stock.
MediumReport
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its price target lowered by analysts at HC Wainwright from $25.00 to $5.00. They now have a "buy" rating on the stock.
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
MediumReport
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: